We’re counting down the days until we’re together in Columbus for FACTOR later this month! In this issue, we’re introducing our new FACTOR HQ Co-Chair and sharing a first look at the FACTOR agenda. We also have an upcoming TURBO meeting, bringing osteosarcoma experts together to review cases and collaborate on treatment options. Plus, meet our new Plus-Plus Hero Agent and explore newly available clinical trials. We can’t wait to reconnect with our community, welcome new faces, and experience all that FACTOR 2026 has in store. See you in Columbus!
With hope,
The MIB Agents team
.png)
FACTOR HQ Co-Chairs Michelle and Sammy help create the welcoming, supportive space that makes HQ such a special part of the FACTOR experience. Get to know new Co-Chair Sammy and hear what she loves most about bringing families, patients, survivors, and caregivers together each year.
The FACTOR 2026 agenda is here! From scientific panels to wellness sessions, this year’s schedule is packed with opportunities to learn, connect, and collaborate. Take a look at what’s planned and start mapping out your FACTOR experience in Columbus.
If you have a job posting and you would like it included here, please email christina@mibagents.org.
If you’re managing a patient with relapsed osteosarcoma and want additional perspectives on treatment strategies or clinical trial options, consider presenting the case at MIB Agents TURBO (Tumor Review Board for Osteosarcoma). TURBO meets via Zoom every two months, bringing together a global panel of osteosarcoma experts to review complex cases, exchange insights, and discuss emerging data. It’s a collegial, multidisciplinary forum designed to support clinical decision-making for challenging cases. This educational forum is for medical professionals only; patients and families are welcome to ask their oncologists to present a case on their behalf. Our next meeting is July 22nd at 5p ET.
Join TURBO to request an invite or submit a case.
Review shared learnings from our ASCO 2026 abstract: Uniting providers across institutions to support osteosarcoma care: Insights from 64 cases reviewed through the MIB agents TURBO board
Coming Up Next on OsteoBites
Your Story, Your Tissue, Your Impact: Changing the Future of Osteosarcoma
.png)
July 9 | Alexander Davies, DVM, PhD (Because of Matthew, in partnership with Fishin' for the Cure))
Validation of MCL1 inhibition and combinatorial therapy for elimination of osteosarcoma lung metastasis
Epigenetic Regulation of the Type I Interferon Pathway in Osteosarcoma: Implications for Immune Checkpoint Blockade
Introducing our new Plus-Plus Hero Agent! Made in Denmark and designed in Greenville, South Carolina, this buildable figure is inspired by the strength of the osteosarcoma community. It will officially launch at FACTOR 2026.
Three clinical trials have recently opened for osteosarcoma patients.
Evaluating Efficacy of B7-H3-CAR T Cells Administered at the End of Upfront Map Chemotherapy in Patients With Newly Diagnosed High-Risk Osteosarcoma recently opened at St. Jude Children's Research Hospital and is enrolling patients <21 with metastatic osteosarcoma at diagnosis. B7-H3-CAR T cells are administered 14-28 days after completing MAP chemotherapy. Contact: referralinfo@stjude.org
OstEvo (A Study of Gefitinib, Trametinib, Disulfiram, and Sunitinib in Addition to Standard Chemotherapy in People With Osteosarcoma) recently opened at Memorial Sloan Kettering Cancer Center and is enrolling newly diagnosed patients ages 6-49 with metastatic high-risk osteosarcoma. Rather than studying one drug at a time, this trial evaluates treatment strategies that combine multiple therapies based on biological insights into how osteosarcoma grows and becomes resistant to treatment. Contact: reedd1@mskcc.org
A Study Evaluating the Efficacy and Safety of Risvutatug Rezetecan in Participants With Advanced Sarcomas (EMBOLD Sarcoma-202) will soon enroll osteosarcoma patients ≥12 with unresectable advanced or metastatic relapsed/refractory disease. The goal of this study is to test a new investigational antibody-drug conjugate (ADC), Risvutatug Rezetecan (Ris-Rez), that targets B7-H3 by combining an anti-B7-H3 monoclonal antibody with a topoisomerase inhibitor payload. Contact: GSKClinicalSupportHD@gsk.com
